Selected studies using myeloablative conditioning and allogeneic transplantation for follicular lymphoma (based on reference1 ).
| Author (No. Pt.) . | Conditioning . | Stem Cell Source . | Median Follow-up (mo) . | PFS . | OS . | TRM* . | Relapse . | Comments . |
|---|---|---|---|---|---|---|---|---|
| * treatment-related mortality occurring in the first year after transplant | ||||||||
| Abbreviations: PFS, progression-free survival; OS, overall survival; VP, etoposide; BM, bone marrow; PB, peripheral blood; CR, complete remission; DLI, donor lymphocyte infusion; Bu/Cy±MEL, busulfan/cyclophosphamide with/without melphalan; NS, not stated specifically; DexaBEAM, dexamethasone/BCNU/etoposide/cytarabine/melphalan; TRM, treatment-related mortality | ||||||||
| Van Besien (113) | TBI 84% Non-TBI 16% | BM | 25 | 49 @ 36mo | 49 @ 36mo | 40% @ 36mo | 16% | Transplants between 1984–1995. One third with small lymphocytic lymphoma |
| Peniket (231) | varied regimens | NS | 60 | 43% @ 48mo | 51% @ 48mo | 38% @ 48mo | 25% | Case-matched study comparing allo with auto. Allo has higher TRM but low relapses |
| Van Besien (176) | TBI 68% Non-TBI 32% | BM 77% PB 23% | 36 | 45% @ 60mo | 51% @ 60mo | 24% @ 12mo | Transplants between 1990–1999 | |
| Mandigers (15) | Cy/TBI | BM | 36 | 67% | 33% | 13% | T cell depleted transplant | |
| Stein (15) | Cy/TBI 93% | BM 93% PB 7% | 60 | NS | 15% | 53% | 33% | |
| Verdonck (15) | Cy/TBI | 25 | 70% | 70% | 27% | 0 | T cell depletion | |
| Toze (16) | NS | BM 100% | 29 | 56% | 25% | 0 | 4 unrelated donors and 12 sibling donors | |
| Forrest (24) | Bu/Cy±MEL 92% | BM 16 PB 8 | 28 | 78% @ 28 mo | 78% @ 28 mo | 21% | 0 | No relapses noted |
| Author (No. Pt.) . | Conditioning . | Stem Cell Source . | Median Follow-up (mo) . | PFS . | OS . | TRM* . | Relapse . | Comments . |
|---|---|---|---|---|---|---|---|---|
| * treatment-related mortality occurring in the first year after transplant | ||||||||
| Abbreviations: PFS, progression-free survival; OS, overall survival; VP, etoposide; BM, bone marrow; PB, peripheral blood; CR, complete remission; DLI, donor lymphocyte infusion; Bu/Cy±MEL, busulfan/cyclophosphamide with/without melphalan; NS, not stated specifically; DexaBEAM, dexamethasone/BCNU/etoposide/cytarabine/melphalan; TRM, treatment-related mortality | ||||||||
| Van Besien (113) | TBI 84% Non-TBI 16% | BM | 25 | 49 @ 36mo | 49 @ 36mo | 40% @ 36mo | 16% | Transplants between 1984–1995. One third with small lymphocytic lymphoma |
| Peniket (231) | varied regimens | NS | 60 | 43% @ 48mo | 51% @ 48mo | 38% @ 48mo | 25% | Case-matched study comparing allo with auto. Allo has higher TRM but low relapses |
| Van Besien (176) | TBI 68% Non-TBI 32% | BM 77% PB 23% | 36 | 45% @ 60mo | 51% @ 60mo | 24% @ 12mo | Transplants between 1990–1999 | |
| Mandigers (15) | Cy/TBI | BM | 36 | 67% | 33% | 13% | T cell depleted transplant | |
| Stein (15) | Cy/TBI 93% | BM 93% PB 7% | 60 | NS | 15% | 53% | 33% | |
| Verdonck (15) | Cy/TBI | 25 | 70% | 70% | 27% | 0 | T cell depletion | |
| Toze (16) | NS | BM 100% | 29 | 56% | 25% | 0 | 4 unrelated donors and 12 sibling donors | |
| Forrest (24) | Bu/Cy±MEL 92% | BM 16 PB 8 | 28 | 78% @ 28 mo | 78% @ 28 mo | 21% | 0 | No relapses noted |